CUL1: A Potential Drug Target for Pancreatic Cancer (G8454)

Target Name: CUL1

NCBI ID: G8454

CUL1: A Potential Drug Target for Pancreatic Cancer

CUL1 (CUL1_HUMAN), a protein that is expressed in various tissues of the human body, including the brain, pancreas, and gastrointestinal tract, has been identified as a potential drug target or biomarker. The study, which was published in the journal Nature Medicine, identified a potential target for the treatment of pancreatic cancer by using a computational approach to identify a unique protein that was expressed in higher levels in pancreatic cancer cells compared to healthy cells.

The study, which was led by Dr. Yueh-Hua Zhou of the University of California, San Diego, involved the use of a computational algorithm to identify a potential target for pancreatic cancer. The algorithm was able to identify CUL1 as a potential target for pancreatic cancer, based on the fact that the level of CUL1 protein was significantly higher in pancreatic cancer cells compared to healthy cells.

\"Our findings suggest that CUL1 may be a promising target for the treatment of pancreatic cancer,\" said Dr. Zhou. \"We are now looking for ways to test our hypothesis and determine if CUL1 can be used as a drug in a clinical trial.\"

CUL1 is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It has been shown to play a role in the development and progression of various diseases, including cancer.

In pancreatic cancer, CUL1 has been shown to be expressed at higher levels in the cancer cells compared to healthy cells. This may be because CUL1 helps to promote the growth and survival of pancreatic cancer cells.

The study that was published in Nature Medicine used a computational approach to identify a potential target for pancreatic cancer. The algorithm was able to identify CUL1 as a potential target based on the fact that the level of CUL1 protein was significantly higher in pancreatic cancer cells compared to healthy cells.

\"We used a computational approach to identify CUL1 as a potential target for pancreatic cancer,\" said Dr. Zhou. \"Our findings suggest that CUL1 may be a promising target for the treatment of pancreatic cancer.\"

While the potential targets identified by the study are an exciting development, it is important to note that further research is needed to determine if CUL1 can be used as a drug in a clinical trial.

In conclusion, the study that was published in Nature Medicine has identified CUL1 as a potential drug target for pancreatic cancer. Further research is needed to determine if CUL1 can be used as a drug in a clinical trial. The discovery of potential drug targets is an important step in the development of new treatments for various diseases.

Protein Name: Cullin 1

Functions: Core component of multiple cullin-RING-based SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. SCF complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins (PubMed:27565346). In the SCF complex, serves as a rigid scaffold that organizes the SKP1-F-box protein and RBX1 subunits. May contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and exchange of the substrate recognition component is mediated by TIP120A/CAND1. The functional specificity of the SCF complex depends on the F-box protein as substrate recognition component. SCF(BTRC) and SCF(FBXW11) direct ubiquitination of CTNNB1 and participate in Wnt signaling. SCF(FBXW11) directs ubiquitination of phosphorylated NFKBIA. SCF(BTRC) directs ubiquitination of NFKBIB, NFKBIE, ATF4, SMAD3, SMAD4, CDC25A, FBXO5 and probably NFKB2. SCF(BTRC) and/or SCF(FBXW11) direct ubiquitination of CEP68 (PubMed:25704143, PubMed:25503564). SCF(SKP2) directs ubiquitination of phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. SCF(SKP2) directs ubiquitination of ORC1, CDT1, RBL2, ELF4, CDKN1A, RAG2, FOXO1A, and probably MYC and TAL1. SCF(FBXW7) directs ubiquitination of CCNE1, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. SCF(FBXW2) directs ubiquitination of GCM1. SCF(FBXO32) directs ubiquitination of MYOD1. SCF(FBXO7) directs ubiquitination of BIRC2 and DLGAP5. SCF(FBXO33) directs ubiquitination of YBX1. SCF(FBXO1) directs ubiquitination of BCL6 and DTL but does not seem to direct ubiquitination of TP53. SCF(BTRC) mediates the ubiquitination of NFKBIA at 'Lys-21' and 'Lys-22'; the degradation frees the associated NFKB1-RELA dimer to translocate into the nucleus and to activate transcription. SCF(CCNF) directs ubiquitination of CCP110. SCF(FBXL3) and SCF(FBXL21) direct ubiquitination of CRY1 and CRY2. SCF(FBXO9) directs ubiquitination of TTI1 and TELO2. SCF(FBXO10) directs ubiquitination of BCL2

More Common Targets